RxDoctor Payments Data

Edward di Preta, MD

Dermatology · Brunswick, GANPI 1689656720

Payments from drug & device makers

$293in general payments, 2019–2025

Across 10 payments — averaging $29.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sebela Pharmaceuticals Inc.$127
  • AbbVie$52
  • Galderma Laboratories, L.p.$36
  • Novartis$28
  • Johnson & Johnson$19
  • Amgen$19
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sebela Pharmaceuticals Inc.1$127
AbbVie2$52
Galderma Laboratories, L.p.2$36
Novartis2$28
Johnson & Johnson1$19
Amgen1$19
Strata Skin Sciences, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$293 in reported general payments places this provider in the 10th percentile of 345 dermatology providers in Georgia.

See all dermatology providers in Georgia

Medicare billing

Part B allowed, 2024
$861,761
Medicare patients
832
Services billed
3,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab47$473,425
Dupixent PenDupilumab76$441,191
TremfyaGuselkumab19$266,124
OtezlaApremilast30$192,815
Cosentyx Sensoready (2 Pens)Secukinumab17$129,232
Clobetasol Propionate382$13,971
Fluocinonide280$12,127
Triamcinolone Acetonide679$11,137
Ketoconazole585$9,067
Mupirocin1,210$8,671
Fluorouracil72$4,592
Tretinoin56$4,425
Metronidazole69$4,090
Tacrolimus38$3,556
CiclopiroxCiclopirox Olamine145$3,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$19$266,12419 claims
AmgenOtezla$19$192,81530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 345 dermatology providers in Georgia.

Other dermatology in Brunswick

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →